Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Earnings Report 5.212 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Despite the Q4 miss, these factors suggest that Eli Lilly holds a promising growth profile ... Citi also maintained a Buy rating on the stock with a $1,250.00 price target. TipRanks tracks over ...

and U.S. supply across all doses of tirzepatide was available throughout Q4," said Lilly CEO David Ricks in a statement. The move in the stock surprised some experts and analysts since the market ...

Results for the fourth quarter of 2024 should show revenue ... The problem, however, goes back to valuation. Eli Lilly is a stock which you might consider to be "priced to perfection" because ...